SJS Investment Consulting’s Actuate Therapeutics ACTU Stock Holding History

SJS Investment Consulting’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-10	Closed	-$16	–	3355
2026 Q2	$16	Buy	10 +9	+900%	+$21	﹤0.01%	2843
2026 Q1	$3	Buy	+1	New	+$4	﹤0.01%	2467

Other funds holding ACTU

Gleason Group Prospect, Kentucky $1.13B AUM 12.68% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

GRWP

Green Ridge Wealth Planning Montville, New Jersey $249M AUM 26.89% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

SJS Investment Consulting's ACTU Position: Q3 2026 in Review

SJS Investment Consulting sold out of Actuate Therapeutics (ACTU) in Q3 2026, closing a stake of 10 shares — an estimated $16 sold.

SJS Investment Consulting first reported a position in ACTU in Q1 2026 and held it in 2 quarters. The position peaked at $16 in Q2 2026. 5 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

SJS Investment Consulting reported no remaining Actuate Therapeutics position as of Q3 2026 after selling out during the quarter.
SJS Investment Consulting sold 10 Actuate Therapeutics shares in Q3 2026, an estimated $16.
SJS Investment Consulting first reported a position in Actuate Therapeutics in Q1 2026 and held it in 2 quarters.
SJS Investment Consulting's Actuate Therapeutics position peaked at $16 in Q2 2026.
5 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.